Live rhizomes in stock · 200 lb totalOrder by email

THE TURMERIC JOURNAL

Turmeric and Metabolic Health: What Trials Show

Promising changes in a blood test are not the same as preventing disease. A careful look at the trials, their effect sizes, and the questions still open.

A blood test makes health look unusually tidy: a glucose number, a cholesterol number, perhaps two liver enzymes. Curcumin research often begins on that tidy page. A supplement is given for several weeks, the numbers are measured again, and the question becomes whether they changed more than they did with placebo.

Some of those results are encouraging. They also leave a larger question open: does the change prevent illness, reduce complications, or help people live longer? The evidence for curcumin is stronger for changes in selected metabolic measurements than for those long-term outcomes. It is primarily evidence about specified supplements, not proof that a serving of turmeric treats diabetes, high cholesterol, high blood pressure, or liver disease.

Four research questions hiding inside “metabolic health”

Metabolic health is a broad label. A study about glucose regulation does not automatically answer a question about cholesterol, and a lower liver-enzyme result does not establish that liver scarring has improved. Before comparing studies, separate the outcome from the health promise attached to it.

What an improvement would—and would not—establish
MeasurementWhat it describesWhat needs additional evidence
Fasting glucose or HbA1cBlood-glucose regulation, measured in different ways and over different timeframes.Durable prevention of diabetes or fewer complications.
LDL cholesterol and triglyceridesComponents of the blood lipid profile.Whether a particular intervention prevents heart attacks or strokes.
Blood pressurePressure in the circulation under the measurement conditions.A reliable, sustained treatment effect and its overall benefits and harms.
ALT, AST, or ultrasound findingsSelected biochemical or imaging features of liver health.Improvement in fibrosis, cirrhosis risk, or liver-related clinical outcomes.

This distinction does not make intermediate measurements unimportant. It keeps a promising signal connected to the question the experiment actually tested. The main turmeric health-evidence guide explains the wider difference between a plausible mechanism, a changed measurement, and a demonstrated benefit.

Blood glucose: a real research signal, with important boundaries

A 2024 synthesis of 103 randomized trials, involving 7,216 participants across 42 outcomes, reported changes in several metabolic measurements. Its authors rated the evidence for fasting blood sugar among their higher-certainty findings, while ratings for many other outcomes were lower. The same review called for larger, longer, better-designed trials. Its size is useful context, but its participants were spread across different outcomes and populations; this was not one 7,216-person diabetes-prevention experiment. Read the 2024 comprehensive meta-analysis.

A narrower 2024 review in people with nonalcoholic fatty liver disease found a small pooled reduction in fasting glucose, while HbA1c did not change significantly. It also identified substantial variation in several other results and concerns about study bias and incomplete independent characterization of the products. Those findings show why “improves blood sugar” is too coarse a summary: one glucose-related outcome can improve while another does not. Read the review of metabolic outcomes in NAFLD.

The relevant comparison is between groups. If glucose falls in the supplement group after participants also change their eating habits, that observation alone cannot assign the improvement to the supplement. Randomized controls help separate those influences. The comparison also needs to preserve the original allocation, explain missing data, and account for other treatments.

The striking diabetes-prevention trial deserves a careful reading

A Thai trial published in 2012 enrolled 240 adults with prediabetes; the results section reports 237 randomized participants. Following a lifestyle-education period, the intervention supplied 1.5 g of curcuminoids daily in an extract for nine months. Diabetes developed in 16.4% of the placebo group and in none of the curcumin group during treatment. Those are the study’s findings, not instructions for supplement use. Read the original trial.

This is more interesting than a small movement in an isolated laboratory marker because new diabetes diagnoses were assessed. It remains one study of a particular population and preparation over a limited period. The result does not establish lifelong protection, show that an existing diagnosis can be reversed, or identify an equivalent amount of fresh turmeric. Independent replication and longer follow-up would make the prevention claim more dependable.

Notice the two sample sizes: the abstract’s enrollment figure and the randomized population are not interchangeable. Reading participant flow is one of the simplest ways to move beyond a headline and see what was actually tested.

Cholesterol: modest pooled changes do not make turmeric a statin substitute

The 2024 NAFLD review reported an average LDL reduction of about 8 mg/dL, with a confidence interval ranging from roughly 0.2 to 15.8 mg/dL lower. Heterogeneity was very high, meaning the study results differed substantially. For scale, 8 mg/dL would be 5% of a hypothetical starting LDL of 160 mg/dL. That arithmetic illustrates magnitude; it does not predict what will happen to an individual. See the lipid estimates and their uncertainty.

The SPORT trial provides a useful counterweight to broad supplement claims. Published in 2023, it compared rosuvastatin, placebo, and six commonly used supplements, including turmeric, over 28 days; 190 participants completed the study. Rosuvastatin produced substantially greater LDL lowering. None of the supplements demonstrated significant LDL reduction versus placebo. Read the original SPORT trial.

That short trial does not prove that every curcumin formulation is ineffective over every duration. It does undermine the assumption that a turmeric product on a shelf can be expected to reproduce a cholesterol medicine’s effect. A positive result for one extract and a null result for another can coexist; they are a reason to identify the actual product and study conditions, not to erase the inconvenient trial.

Blood pressure: newer evidence is more specific than the broad claim

A 2023 review of 17 trials and 1,377 participants found no significant overall effect on systolic or diastolic pressure. The pooled estimates were close to zero. Some subgroup results were positive, but a favorable subgroup should not replace the overall result without a convincing reason. Read the 2023 blood-pressure meta-analysis.

A later review, published online in December 2025, focused specifically on prediabetes and type 2 diabetes. It included 15 randomized trials with 855 participants and found a pooled systolic reduction of 2.69 mmHg; the 95% confidence interval was 1.55 to 3.84 mmHg lower. The overall diastolic result was not significant. Read the diabetes-focused review.

The two reviews ask overlapping but different questions. The later result offers a modest signal in a defined population, not a guarantee for anyone with high blood pressure. Even a small sustained change can be worth studying. Establishing how reliably it occurs, which formulation produces it, and whether benefits outweigh harms requires more than choosing the most favorable pooled estimate.

Fatty liver: improved enzymes are not the same as repaired liver tissue

Much of this literature uses the older term NAFLD. The newer name MASLD—metabolic dysfunction-associated steatotic liver disease—places metabolic risk factors within the definition. The diagnostic framework also changed, so study eligibility deserves attention when applying older findings. Read the multisociety nomenclature consensus.

A 2022 review of 16 trials and 1,028 participants reported favorable ultrasound findings and reductions in some liver enzymes. A separate 2024 analysis found no significant pooled improvements in several enzyme and metabolic outcomes. Different inclusion criteria, methods, formulations, and study populations can change the pooled answer. Read the 2022 review and the 2024 analysis.

A 2023 reassessment also called for better evidence about liver histology, fibrosis, and steatosis. That is the clinical gap to keep in view: an enzyme reduction does not by itself demonstrate less scarring or fewer future liver complications. Read the updated liver review.

There is a further complication: turmeric supplements have themselves caused rare liver injury. A substance being investigated for one liver condition is not automatically safe for every liver. Our supplement-safety guide explains that evidence without confusing an extract with ordinary seasoning.

What would make the evidence more useful?

The most valuable next studies would specify and independently analyze the preparation, recruit enough people to obtain precise results, and follow them long enough to assess meaningful outcomes. They would report adverse events systematically and show whether findings hold outside one research center. They would also distinguish adding curcumin to established care from replacing that care.

Several reviews can contain the same underlying trials. Seeing five favorable meta-analyses does not necessarily mean five independent sets of patients confirmed the effect. The ingredients of the evidence matter as much as the number of papers. A useful review states its search dates, eligibility rules, risk-of-bias judgments, and whether one influential trial changes the conclusion when removed.

For now, the balanced reading is that curcumin has credible metabolic research signals, with effect size and certainty varying by outcome. Evidence of fewer heart attacks, strokes, or long-term diabetes complications is not supplied by the short biomarker studies discussed here.

Where culinary turmeric fits

There is room to enjoy turmeric without turning dinner into a treatment experiment. Its role in a meal can be flavor, color, and variety. The overall food pattern remains a different intervention from swallowing a concentrated extract. NIDDK’s dietary guidance for fatty liver focuses on the broader pattern of foods and metabolic health, not a turmeric prescription. Read NIDDK’s nutrition guidance.

Adding pepper does not close the evidence gap: increased absorption is a separate claim from improved health. For adjacent questions, explore the evidence on joint pain, digestive health, and memory and mood. These studies do not establish therapeutic effects for our farm’s fresh turmeric or powder.

Sources & further reading

  1. Comprehensive curcumin meta-analysis: 103 randomized trials and 42 outcomes (2024)
  2. Curcumin and metabolic outcomes in nonalcoholic fatty liver disease: systematic review and meta-analysis (2024)
  3. Chuengsamarn and colleagues — Curcumin extract for prevention of type 2 diabetes (2012)
  4. Laffin and colleagues — Comparative effects of low-dose rosuvastatin, placebo, and dietary supplements: SPORT (2023)
  5. Curcumin supplementation and blood pressure: meta-analysis of randomized trials (2023)
  6. Curcumin and blood pressure in prediabetes and type 2 diabetes: systematic review and meta-analysis (published online December 2025)
  7. Multisociety Delphi consensus on new fatty liver disease nomenclature (2023)
  8. Curcumin supplementation in nonalcoholic fatty liver disease: 16-trial meta-analysis (2022)
  9. Curcumin effects on liver enzymes and metabolic measurements in NAFLD: meta-analysis (2024)
  10. Curcumin in nonalcoholic fatty liver disease: updated meta-analysis and umbrella review (2023)
  11. NIDDK — Eating, Diet, and Nutrition for NAFLD and NASH

Keep following the evidence.

This series explains published research for general information; it does not provide personal medical advice. Study formulations and doses describe experiments, not instructions for self-treatment.

Explore the complete health seriesRead the safety and interactions guide